Eli Lilly and Immuneering Partner for Lung Cancer Drug Trials

Immuneering has partnered with Eli Lilly for lung cancer drug trials. Eli Lilly is a leading pharmaceutical company with a focus on endocrinology, oncology, immunology diseases, and neurology. Net sales are primarily generated in the US, Europe, Japan, China, and other regions.

Title: Immuneering Partners with Eli Lilly for Advanced Lung Cancer Drug Trials

Immuneering Corporation (Nasdaq: IMRX) has announced a clinical supply agreement with Eli Lilly and Company (NYSE: LLY) to evaluate its lead product candidate, atebimetinib (IMM-1-104), in combination with Eli Lilly's second-generation KRAS G12C inhibitor, olomorasib (LY3537982), in a planned Phase 2 clinical trial. The trial aims to assess the potential of this dual-targeted approach in patients with locally advanced or metastatic KRAS G12c-mutant non-small cell lung cancer (NSCLC) who have progressed on prior therapy.

The agreement, announced on August 25, 2025, marks the second collaboration this year for Immuneering, following a similar agreement with Regeneron Pharmaceuticals in February 2025. This trial is part of Immuneering's strategy to evaluate atebimetinib in combination with synergistic anti-cancer mechanisms, particularly in challenging tumor types such as NSCLC.

E.B. Brakewood, Chief Business Officer of Immuneering, stated, "This agreement with Lilly marks the second such collaboration we have announced this year as we seek to evaluate the potential of atebimetinib in combination with synergistic anti-cancer mechanisms. A pan-MAPK solution is of particular interest in challenging tumor types such as NSCLC."

Dr. Igor Matushansky, MD, PhD, Chief Medical Officer of Immuneering, noted, "The combination of atebimetinib and olomorasib has the potential to provide a vertical blockade of the RAS-MAPK pathway. Preclinical studies have shown enhanced tumor regression, delayed emergence of tumor resistance, and prolonged survival relative to monotherapy. This dual targeted approach has the potential to improve outcomes in a population with limited effective treatment options."

Immuneering will maintain global development and commercialization rights to atebimetinib. The company's lead product candidate is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer.

This collaboration underscores Immuneering's commitment to advancing innovative cancer treatments and highlights the potential of combining targeted therapies to improve patient outcomes. The trial is expected to provide valuable insights into the efficacy of atebimetinib in combination with olomorasib in a challenging patient population.

References:
[1] https://www.morningstar.com/news/globe-newswire/9517207/immuneering-announces-clinical-supply-agreement-with-lilly-to-evaluate-atebimetinib-in-combination-with-olomorasib
[2] https://www.marketscreener.com/news/immuneering-announces-clinical-supply-agreement-with-lilly-to-evaluate-atebimetinib-in-combination-w-ce7c50d8d889f121